Navigation Links
Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
Date:12/7/2007

ompany's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6More Swine Flu Vaccine Coming Soon 60183 1More Swine Flu Vaccine Coming Soon 60183 2More Swine Flu Vaccine Coming Soon 60183 3Highmark Recognized as One of Americas Healthiest Companies 60178 1Highmark Recognized as One of Americas Healthiest Companies 60178 2Anthem Blue Cross and Blue Shield in Missouri Earns NCQA Accreditation Status of Excellent 60173 1Anthem Blue Cross and Blue Shield in Missouri Earns NCQA Accreditation Status of Excellent 60173 2